Glucagon as a critical factor in the pathology of diabetes

Diabetes

Volumn 60, Issue 2, 2011, Pages 377-380

  Edgerton, Dale S ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; STREPTOZOCIN;

DIABETES MELLITUS; GENE INACTIVATION; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; LIPOLYSIS; NONHUMAN; NOTE; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; DIABETES MELLITUS, TYPE 1; GLUCAGON; MICE; MICE, KNOCKOUT; RECEPTORS, GLUCAGON;

EID: 79551582075     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1594     Document Type: Note

References (35)

1. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice. Diabetes 2011; 60:391-397
2. Conarello SL, Jiang G, Mu J, et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007;50:142-150
3. Wang MY, Chen L, Clark GO, et al. Leptin therapy in insulin-deficient type I diabetes. Proc Natl Acad Sci USA 2010;107:4813-4819
4. Hancock AS, Du A, Liu J, Miller M, May CL. Glucagon deficiency reduces hepatic glucose production and improves glucose tolerance in adult mice. Mol Endocrinol 2010;24:1605-1614
5. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 2009;296: E415-E421
6. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28:253-283
7. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deficient type 1 diabetic rodents thrive without insulin. Proc Natl Acad Sci USA 2008;105:14070-14075
8. Stevenson RW, Williams PE, Cherrington AD. Role of glucagon suppression on gluconeogenesis during insulin treatment of the conscious diabetic dog. Diabetologia 1987;30:782-790
9. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995; 38:337-343
10. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053-4059
11. Boden G, Master RW, Rezvani I, Palmer JP, Lobe TE, Owen OE. Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. J Clin Invest 1980;65:706-716
12. Del Prato S, Tiengo A, Baccaglini U, et al. Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy. Diabetologia 1983;25:252-259
13. Vranic M, Pek S, Kawamori R. Increased "glucagon immunoreactivity" in plasma of totally depancreatized dogs. Diabetes 1974;23:905-912
14. Moore MC, Cherrington AD, Wasserman DH. Regulation of hepatic and peripheral glucose disposal. Best Pract Res Clin Endocrinol Metab 2003; 17:343-364
15. Pagliassotti MJ, Moore MC, Neal DW, Cherrington AD. Insulin is required for the liver to respond to intraportal glucose delivery in the conscious dog. Diabetes 1992;41:1247-1256
16. Liljenquist JE, Mueller GL, Cherrington AD, et al; Chiasson J-L. Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man. J Clin Invest 1977;59:369-374
17. Cherrington AD, Lacy WW, Chiasson JL. Effect of glucagon on glucose production during insulin deficiency in the dog. J Clin Invest 1978;62:664-677
18. Chen SS, Santomango TS, Williams PE, Lacy DB, McGuinness OP. Glucagon- mediated impairments in hepatic and peripheral tissue nutrient disposal are not aggravated by increased lipid availability. Am J Physiol Endocrinol Metab 2009;296:E1172-E1178
19. Chen SS, Zhang Y, Santomango TS, Williams PE, Lacy DB, McGuinness OP. Glucagon chronically impairs hepatic and muscle glucose disposal. Am J Physiol Endocrinol Metab 2007;292:E928-E935
20. Yki-Järvinen H, Young AA, Lamkin C, Foley JE. Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest 1987;79:1713-1719
21. Jackson RA, Roshania RD, Hawa MI, Sim BM, DiSilvio L. Impact of glucose ingestion on hepatic and peripheral glucose metabolism in man: an analysis based on simultaneous use of the forearm and double isotope techniques. J Clin Endocrinol Metab 1986;63:541-549
22. Wasserman DH. Four grams of glucose. Am J Physiol Endocrinol Metab 2009;296:E11-E21
23. Moller DE, Chang PY, Yaspelkis BB 3rd, Flier JS, Wallberg-Henriksson H, Ivy JL. Transgenic mice with muscle-specific insulin resistance develop increased adiposity, impaired glucose tolerance, and dyslipidemia. Endocrinology 1996;137:2397-2405
24. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 2000;6:924-928
25. Brüning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998;2:559-569
26. Charron MJ, Gorovits N, Laidlaw JS, Ranalletta M, Katz EB. Use of GLUT-4 null mice to study skeletal muscle glucose uptake. Clin Exp Pharmacol Physiol 2005;32:308-313
27. Longuet C, Sinclair EM, Maida A, et al. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab 2008;8:359-371
28. Carlson MG, Snead WL, Campbell PJ. Regulation of free fatty acid metabolism by glucagon. J Clin Endocrinol Metab 1993;77:11-15
29. Gravholt CH, Møller N, Jensen MD, Christiansen JS, Schmitz O. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab 2001;86:2085-2089
30. Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:121-124
31. Redondo A, Trigo MV, Acitores A, Valverde I, Villanueva- Peñacarrillo ML. Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 2003; 204:43-50
32. González N, Acitores A, Sancho V, Valverde I, Villanueva- Peñacarrillo ML. Effect of GLP-1 on glucose transport and its cell signalling in human myocytes. Regul Pept 2005;126:203-211
33. Dardevet D, Moore MC, DiCostanzo CA, et al. Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol 2005;289:G806-G814
34. Johnson KM, Edgerton DS, Rodewald T, et al. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 2007;293:E1085-E1091
35. Gu W, Winters KA, Motani AS, et al. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. Am J Physiol Endocrinol Metab 2010;299:E624-E632s